Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Ipilimumab + AG in Advanced Biliary Tract Cancers
NCT07654530Phase 2Active, not recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in biliary tract cancer (BTC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Apr 2026; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07654530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07654530.